{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:50:10Z","timestamp":1785783010241,"version":"3.56.0"},"reference-count":10,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Heart Failure"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jchf.2026.103114","type":"journal-article","created":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T18:57:11Z","timestamp":1779217031000},"page":"103114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enabling a Renin-Angiotensin System Inhibitor and\/or a Mineralocorticoid Receptor Antagonist in Patients With Heart Failure and\/or Chronic Kidney Disease"],"prefix":"10.1016","volume":"14","author":[{"given":"Bertram","family":"Pitt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javed","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jchf.2026.103114_bib1","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jchf.2022.06.010","article-title":"Steroidal MRA across the spectrum of renal function. A pooled analysis of RCTs","volume":"10","author":"Ferreira","year":"2022","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103114_bib2","first-page":"685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatine: is this a cause for concern?","volume":"160","author":"Bakri","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jchf.2026.103114_bib3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s40620-021-01070-6","article-title":"Association between hyperkalemia, RAASi non-adherence and outcomes in chronic kidney disease","volume":"35","author":"Santoro","year":"2022","journal-title":"J Nephrol"},{"key":"10.1016\/j.jchf.2026.103114_bib4","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1001\/jamacardio.2016.4733","article-title":"Reduced risk of hyperkalemia during treatment of heart failure with mineralocorticoid receptor antagonists by use of sacubitril\/valsartan compared with enalapril: a secondary analysis of the PARADIGM-HF trial","volume":"2","author":"Desai","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jchf.2026.103114_bib5","doi-asserted-by":"crossref","first-page":"2984","DOI":"10.1093\/eurheartj\/ehac306","article-title":"Empagliflozin and serum potassium in heart failure: an analysis from EMPEROR-Pooled","volume":"43","author":"Ferreira","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jchf.2026.103114_bib6","first-page":"1062","article-title":"Sodium zirconium cyclosilicate-associated adverse events: an analysis of the FAERS database","volume":"5","author":"Yamin","year":"2024","journal-title":"J Clin Pharmacol Ther"},{"key":"10.1016\/j.jchf.2026.103114_bib7","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.cardfail.2022.04.003","article-title":"Risk of hospitalization for heart failure in patients with hyperkalemia treated with sodium zirconium cyclosilicate versus patiromer","volume":"28","author":"Zhuo","year":"2022","journal-title":"J Card Fail"},{"key":"10.1016\/j.jchf.2026.103114_bib8","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1002\/ehf2.14268","article-title":"Potassium reduction with sodium zirconium cyclosilicate in patients with heart failure","volume":"10","author":"Tardif","year":"2023","journal-title":"ESC Heart Fail"},{"key":"10.1016\/j.jchf.2026.103114_bib9","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.34067\/KID.0000000586","article-title":"The association of heart failure and edema events between patient initiated sodium-zirconium cyclosilicate or patiromer","volume":"5","author":"Desai","year":"2024","journal-title":"Kidney360"},{"key":"10.1016\/j.jchf.2026.103114_bib10","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/ki.1989.190","article-title":"Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril","volume":"36","author":"Heeg","year":"1989","journal-title":"Kidney Int"}],"container-title":["JACC: Heart Failure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177926002143?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213177926002143?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T18:41:41Z","timestamp":1785782501000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213177926002143"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":10,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2213177926002143"],"URL":"https:\/\/doi.org\/10.1016\/j.jchf.2026.103114","relation":{},"ISSN":["2213-1779"],"issn-type":[{"value":"2213-1779","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enabling a Renin-Angiotensin System Inhibitor and\/or a Mineralocorticoid Receptor Antagonist in Patients With Heart Failure and\/or Chronic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"JACC: Heart Failure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jchf.2026.103114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation. Published by Elsevier.","name":"copyright","label":"Copyright"}],"article-number":"103114"}}